* If you want to update the article please login/register
Thirty-eight adult men and women with DM2 will be recruited from the University of Minnesota and surrounding areas, and will be randomized to LoBAG diet or a control diet. Following a consent and screening visit, there will be five more study visits throughout a 12-week diet intervention period. The study will be conducted at baseline, week 1, week 6, week 9 and week 12, with week 9 and week 12. In addition to scheduled study visits, the research team will phone call participants every other week to discuss any concerns that arise, with the intention of increasing participation and retention. Participants will be contacted once in weeks 9-12 for a 24-hour diet recall collected by the University of Minnesota's Nutrition Coordinating Center. After the 12-week diet intervention period and analysis of all outcome measures, all outcome measures will come to an end.
Source link: https://clinicaltrials.gov/ct2/show/NCT02717078
Hence, NAD+ support services and steps to prevent NAD+ depletion with age have drew major attention. NAD+ and antioxidant aging are both shown in NAD+ increments and support healthy aging. Both nicotinamide mononucleotide and nicotinamide riboside are orally bioavailable and appear to increase NAD+ levels more effectively than nicotinamide riboside. Single orally administered doses of 100-500 mg were safe and well tolerated, according to the first scientific study into the safety and bioavailability of NMN supplementation. There are currently five published clinical trials looking at the effects of NMN supplementation on metabolic variables such as glucose and insulin metabolism, lipid levels, body composition, and hormone levels. As part of a standard of care, including Dietary Approaches to Stop Hypertension, the Dietary Approaches to Stop Hypertension, were implemented by dietary interventions to reduce hypertension. Indeed, both low-carbohydrate and low-fat dietary strategies have been shown to reduce systolic BP and diastolic BP. A low carbohydrate intake is thought to be one of the causes of elevated blood pressure, so a low carbohydrate diet in combination with the supplement is hypothesized to result in beneficial blood pressure improvements, while still promoting factors that promote healthy blood flow and oxygen delivery in the body. If systolic SBP is u2265 100 mmHg, or diastolic DBP is u2265 100 mmHg, according to Hypertension Canada's 2020 Comprehensive Guidelines for Prevention, Diagnos, Risk Assessment, and Treatment of Hypertension in Adults and Children, patients at risk of having no other identifiable organ or cardiovascular risk factors. Participants in this research represent a target population that will profit from safe and efficacious nutraceuticals for regulation of BP without the added burden of side effects that are often associated with angiotensin converting enzyme inhibitors, thus reducing the complexity of polypharmacy. Hypertensives can therefore be enrolled in therapeutic plans that needed prescription medications of ACE inhibitors, according to the new report. Participants aged 45 to 65 years will be eligible for enrollment to prevent complications due to advanced age and a body mass index of up to 32. 9 kg/m2 will eliminate confounders related to advanced obesity. To exclude individuals with an elevated risk of obesity-related disorders, gender-specific waist circumference cut-offs of less than 102 cm in men and 88 cm in women will be used.
Source link: https://clinicaltrials.gov/ct2/show/NCT05298410
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions